Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Relieves nasal and non-nasal symptoms. Sold as Clarinex. Every FDA application for this active ingredient: 6 branded and 13 generic.
As of Nov 15, 2026, FDA lists 19 applications for Desloratadine (sold as Clarinex), first approved Dec 21, 2001, with 0 new uses approved and 0 published complete response letters.
First approved: Dec 21, 2001
Applications: 19
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $7.0M
First approved in the EU: Jan 15, 2001
First approved in Japan: Sep 28, 2016
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Desloratadine
Part D
$6.8M
-1%
54,960
Clarinex
Part D
$255K
+1%
110
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
DESLORATADINE 5 MG ODT: $4.74 per unitGeneric · +25% in a year
DESLORATADINE 5 MG TABLET: $0.256 per unitGeneric · -17% in a year
CLARINEX 5 MG TABLET: $8.85 per unitBrand · +5% in a year
Approvals in the EU (EMA)
First approved in the EU 11 months before the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
AllexSchering-Plough Europe · Jan 15, 2001 · withdrawn
Approvals in Japan (PMDA)
First approved in Japan 177 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Desalex, new ingredientA drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases… · MSD K.K. · Sep 28, 2016
Clinical Trials
9 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Organon
Schering
Lupin Pharms
Sun Pharm Inds
Perrigo
Zydus Pharms USA